Cluenex
Log inStart free
All stocks · Healthcare · Health Care Equipment

Dexcom DXCM

Dexcom scores excellent on business quality (8.4 of 10). Here is why, in plain words, and what our sealed record shows.

Last price$84.11Oct 9, 2026
Business qualityExcellent
Next earningsOct 22, 2026
Insiders, 90 daysQuiet

Why it matters

  1. What Dexcom does

    Dexcom designs and manufactures continuous glucose monitoring systems. Diabetes patients buy these wearable sensors to track blood sugar levels in real time without finger pricks.

  2. What it does best

    Dexcom locks in patients through continuous glucose monitoring technology. It generates a free cash flow margin of 28.3%, ranking in the top quartile of its sector at 85. Switching ecosystems is difficult because sensors integrate tightly with insulin pumps and mobile apps.

  3. The main risk

    Competition from rivals like Medtronic threatens market share. If alternative exchange offers and devices capture new Type 2 patients, revenue growth will slow from its current pace.

Quality, check by check

Scored against its own industry, from company filings.

ProfitabilityStrong

Gross margin sits at 64.3% with an operating margin of 22.9%. High return on equity of 36.2% proves the business becomes significantly more profitable as it scales.

MoatStrong

Switching costs and proprietary sensor tech lock in chronic patients and healthcare providers. Its revenue growth ranks in the top quartile of its sector at the 80th percentile.

GrowthFast

Revenue grew 15.6% over the latest period, supported by expanding adoption in Type 2 diabetes care. This top-line expansion beats historical levels.

Financial healthStrong

Debt-to-equity sits at 0.5 with interest coverage at 75.9x: debt costs are a non-issue. Free cash flow surged to $1.4B, showing a rapidly strengthening cash position.

Insiders

Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.

No open market buys or unplanned sales by executives or directors.

Our sealed record on DXCM

Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.

The first sealed verdicts appear here on Oct 11, 2026.

Questions

Is DXCM a good business?

Dexcom scores excellent on the Cluenex quality check (8.4 of 10), measured against its own industry. Profitability is strong, moat strong, growth fast and financial health strong.

Are insiders buying DXCM?

In the last 90 days of SEC Form 4 filings: No open market buys or unplanned sales by executives or directors.

When does DXCM report earnings?

Oct 22, 2026.

For members

See DXCM today

  • Today's verdict on DXCM, and why
  • Fair value with cautious, base and optimistic cases
  • The exact price that would change the verdict
  • Which stocks each signal names, the night it fires
Open in Cluenex Free to start. First month of Core free.

Cite this page: Cluenex, “Dexcom (DXCM)”, https://cluenex.com/stocks/dxcm/, data as of Oct 10, 2026.